# Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

> **NCT00593008** · PHASE1 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 5 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Temsirolimus
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00593008
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2011-12-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00593008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00593008, "Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00593008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*